Promising Results From a New Treatment Regimen in Primary Unresectable Hepatocellular Carcinoma
In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients
[5:08 PM] Cinzia POZZI - ESMOchange the subtitle into: In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients
CROWN Trial Supports Lorlatinib as a Future First-line Standard Treatment in ALK-positive Non-small Cell Lung Cancer
The ALK tyrosine kinase inhibitor lorlatinib significantly improved progression-free survival compared with crizotinib
Encouraging Long-Term Survival Benefits with Atezolizumab Plus Nab-Paclitaxel in Metastatic Triple-Negative Breast Cancer
Mixed results from IMpassion 130 and IMpassion 131 also draw attention to chemotherapy backbone selection
ASCENT: A Landmark Advance in Treating Refractory Triple-Negative Breast Cancer
In the Phase III trial, sacituzumab govitecan significantly improved progression-free survival and overall survival over standard chemotherapy
SOLAR-1 Trial Reports Overall Survival Benefits in Breast Cancer Patients with Limited Options of Treatment
Results support the use of alpelisib plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer and PI3KCA mutations
How is COVID-19 Affecting the Wellbeing of Oncology Professionals?
Dr Susana Banerjee summarises results from two surveys investigating the psychological impact of the pandemic on medical oncologists
Intensive Follow-up Increases Frequency of Curative Intent Secondary Surgery in Colorectal Cancer
Results from the PRODIGE 13 trial, presented at ESMO Virtual Congress 2020, show that optimisation of diagnostic procedures in terms of overall survival benefits remains to be determined
Neoadjuvant Immunotherapy Does Not Find Its Place Yet in Resectable NSCLC
Although disappointing, results from IONESCO and PRINCEPS trials are preliminary
Is Precision Medicine Fulfilling its Promise?
The delivery of precision medicine is still restricted by clinicians’ capability to interpret the genomic alterations and match them with the most appropriate medicines
Dozens of COVID19-Related Articles Retracted: How to Assess the Quality of Research in the COVID-19 Era
Dr Alessandra Curioni-Fontecedro shares her perspectives on the pitfalls of peer reviewing and its impact on the scientific community and the society